ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cutaneous"

  • Abstract Number: 0979 • ACR Convergence 2022

    Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials

    Susan Manzi1, Jorge Sanchez-Guerrero2, Naoto Yokogawa3, Joerg Wenzel4, Josephine C. Ocran-Appiah5, Munther Khamashta6, Julia H N Harris7, Bernie Rubin8, Norma Lynn Fox9, Roger A Levy10 and Victoria Werth11, 1Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, 2University of Toronto, Division of Rheumatology, Department of Medicine Mount Sinai Hospital/University Health Network, Toronto, ON, Canada, 3Tokyo Metropolitan Tama Medical Center, Department of Rheumatic Diseases, Tokyo, Japan, 4University Hospital of Bonn, Department of Dermatology and Allergy, Bonn, Germany, 5GlaxoSmithKline, Clinical Science Immunology, Rockville, MD, 6GlaxoSmithKline, Medical Affairs, Dubai, United Arab Emirates, 7GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, 8GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, 9GlaxoSmithKline, Clinical Development *At time of study, Collegeville, PA, 10GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 11Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia

    Background/Purpose: Mucocutaneous manifestations affect >80% of patients (pts) with SLE and can contribute to their poor quality of life through unwanted attention, self-consciousness, emotional symptoms,…
  • Abstract Number: 1577 • ACR Convergence 2022

    Impact of Cutaneous Vasculitis on Health-Related Quality-of-Life

    Sarah Mann1, Aamir Hussain2, Anisha Dua3, Angelina Patrone4, Kalen Larson5, Peter Merkel6 and Robert Micheletti7, 1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2Department of Dermatology, Georgetown University, Washington, DC, 3Northwestern University, Chicago, IL, 4Patient Partner, Philadelphia, PA, 5Vasculitis Foundation, Kansas City, MO, 6University of Pennsylvania, Philadelphia, PA, 7Departments of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Cutaneous manifestations of vasculitis can cause pruritus, pain, and ulceration, and their psychosocial impacts may be significant. However, the quality-of-life (QoL) impact of skin…
  • Abstract Number: 1664 • ACR Convergence 2022

    TRIM21 as a Regulator of UVB-Driven IFN Responses in Lupus

    Richard Moore, Gantsetseg Tumurkhuu, Daniel Wallace and Caroline Jefferies, Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) experience photosensitivity where exposure to ultraviolet light B (UVB) drives lupus flares and systemic symptoms. Although the mechanisms…
  • Abstract Number: 1692 • ACR Convergence 2022

    Interferon Alpha Promotes Ultraviolet Light-Mediated Keratinocyte Apoptosis in a Caspase-8 Dependent Manner via Upregulation of Interferon Regulatory Factor 1

    Shannon Estadt, Mehrnaz Gharaee-Kermani, Bin Xu, Tyson Moore, Andrew Hannoudi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by enhanced sensitivity to ultraviolet radiation (UVR). UVR can trigger cutaneous and systemic disease…
  • Abstract Number: 1696 • ACR Convergence 2022

    Single Cell RNA-seq Identifies Major Shifts in Myeloid Cells in Dermatomyositis Skin and Peripheral Blood Compared to Systemic Lupus

    Grace Hile, Feiyang Ma, Amanda Victory, Bin Xu, Mehrnaz Gharaee-Kermani, Elisabeth Pedersen, Rachael Wasikowski, Celine Berthier, Vladimir Ognenovski, Allison Billi, Johann Gudjonsson and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

    Background/Purpose: Skin disease in dermatomyositis (DM) is relapsing and often refractory to treatment, reflecting a lack of understanding of the mechanisms driving skin inflammation. DM…
  • Abstract Number: 1710 • ACR Convergence 2022

    CCL2 Drives Interferon-enhanced Monocytosis in UV-mediated Skin Injury in Murine Lupus

    Mitra Maz1, Hong Shi2, Sonya Wolf-Fortune3, Shannon Estadt3, Alayka Reddy3, Rachael Wasikowski3, Alex Tsoi3, Celine Berthier3 and J. Michelle Kahlenberg3, 1University of Michigan Medical School, Ann Arbor, MI, 2Department of Internal Medicine/Division of Rheumatology, Vascular Biology Center, Augusta, GA, 3University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by overproduction of type I interferons (IFNs) and sensitivity to ultraviolet (UV) light. Though…
  • Abstract Number: 0208 • ACR Convergence 2022

    Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A) and Associated Patient-Reported Outcomes and Biomarkers in a Phase 2 Clinical Trial in Dermatomyositis (DM)

    Josh Dan1, Jay Patel2, Grant Sprow3, DeAnna Diaz4, Nilesh Kodali5, Rui Feng6, Barbara White7 and Victoria Werth8, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 2Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN, 3Albert Einstein College of Medicine, Philadelphia, PA, 4Philadelphia College of Medicine, Philadelphia, PA, 5New Jersey Medical School, Coppell, TX, 6University of Pennsylvania, Philadelphia, 7SFJ Pharmaceuticals, Towson, MD, 8University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

    Background/Purpose: Retrospective reviews of clinical databases from two sites have identified strong relationships between patient-reported outcomes and skin activity in DM, as measured by CDASI-A.…
  • Abstract Number: 1766 • ACR Convergence 2022

    COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis

    Angie El-Said1, Areeb Ahmad2, Massimo Valenti3, Neel K. Shah1, Susana Soto1 and Shazia Beg4, 1University of Central Florida College of Medicine, Orlando, FL, 2University of Central Florida, Orlando, FL, 3Sapienza University of Rome, School of Medicine, Rome, Italy, 4UCF, Orlando, FL

    Background/Purpose: Although various systemic and dermatologic manifestations associated with COVID-19 have been reported in the literature, investigations of how these manifestations vary by race remain…
  • Abstract Number: 0211 • ACR Convergence 2022

    Determinants of COVID-19 Vaccine Hesitancy in a Predominantly Black Population with Cutaneous Lupus Erythematosus

    Sophia Lutgen1, S. Sam Lim2, Laura D. Aspey2, Gaobin Bao3, Charmayne Dunlop-Thomas2, Jessica N. Williams2 and Cristina Drenkard2, 1Mount Sinai Morningside-West, New York, NY, 2Emory University, Atlanta, GA, 3Emory University School of Medicine, Atlanta, GA

    Background/Purpose: Due to demographic and disease-related factors, patients with lupus are deemed to be more vulnerable to COVID-19 infection than the general population, but they…
  • Abstract Number: 1848 • ACR Convergence 2022

    Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope

    Josh Dan1, Grant Sprow2, Josef Concha3, Nilesh Kodali4, DeAnna Diaz5, Felix Chin6, Thomas Vazquez7 and Victoria Werth3, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 2Albert Einstein College of Medicine, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA, 4New Jersey Medical School, Coppell, TX, 5Philadelphia College of Medicine, Philadelphia, PA, 6University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 7FIU Wertheim College of Medicine, Virginia Beach, VA

    Background/Purpose: Nailfold capillary (NC) abnormalities are increasingly utilized in the evaluation of rheumatic conditions. Their presence can distinguish primary Raynaud's phenomenon from secondary etiologies and…
  • Abstract Number: 0318 • ACR Convergence 2022

    Development and Validation of Algorithms to Identify Cutaneous Lupus Patients Using Diagnostic Codes and Prescription Data

    Lisa Guo1, Jordan Said2, Vinod Nambudiri3 and Joseph Merola3, 1Brigham and Women's Hospital, Boston, MA, 2Harvard Medical School, Boston, MA, 3Harvard Medical School, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: There is a paucity of epidemiological studies of cutaneous lupus erythematosus (CLE), which may be due in part to the lack of well-validated methods…
  • Abstract Number: 1862 • ACR Convergence 2022

    Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial

    Thomas Vazquez1, Meena Sharma1, Rui Feng2, DeAnna Diaz3, Nilesh Kodali1, Josh Dan3, Madison Grinnell3, Emily Keyes3, Grant Sprow3, Barbara White4 and Victoria Werth3, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, 3Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 4Corbus Pharmaceuticals, Pleasanton, CA

    Background/Purpose: Dermatomyositis (DM) is an autoimmune connective tissue disease that primarily affects the skin and lung; few effective treatment options are available. Lenabasum is a…
  • Abstract Number: 0598 • ACR Convergence 2021

    Differences in Discoid Lupus Erythematosus Skin Lesion Distribution and Characteristics in Black and Non-Black Patients: A Retrospective Cohort Study

    Adrienne Joseph, Brandon Windsor, Linda Hynan and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Epidemiological studies have shown that discoid lupus erythematosus (DLE) has a higher incidence and prevalence in minorities, particularly Black individuals. Racial differences in clinical…
  • Abstract Number: 0970 • ACR Convergence 2021

    Hippo Signaling Is a Novel Regulator of Apoptosis and Photosensitivity in Lupus Keratinocytes

    Grace Hile1, Patrick Coit2, Bin Xu1, Shannon Estadt1, Jacob Martens3, Rachael Wasikowski1, Lam Tsoi1, Ramiro Iglesias-Bartolome4, Celine Berthier1, Allison Billi5, Johann Gudjonsson5, Amr Sawalha2 and J. Michelle Kahlenberg1, 1University of Michigan, Ann Arbor, MI, 2University of Pittsburgh, Pittsburgh, PA, 3Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, 4NIH, National Cancer Institute, Bethesda, MD, 5Department of Dermatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Skin inflammation and photosensitivity are common manifestations of cutaneous (CLE) and systemic lupus erythematosus (SLE), yet the mechanisms underlying heightened cell death and epidermal…
  • Abstract Number: 1043 • ACR Convergence 2021

    Prevalence of Multimorbidity in Cutaneous Lupus Erythematosus: A Population-Based Study

    Mehmet Hocaoglu1, Mark Davis2, Maria Valenzuela-Almada3, Jesse Dabit2, Shirley-Ann Osei-Onomah2, Sebastian Vallejo-Ramos2, Tina Gunderson2, Kurt Greenlund4, Kamil Barbour4, Cynthia Crowson5 and Ali Duarte-Garcia2, 1University of Maryland Medical Center, Midtown Campus, Baltimore, MD, 2Mayo Clinic, Rochester, MN, 3Division of Rheumatology, Mayo Clinic, Rochester, MN, 4Centers for Disease Control, Atlanta, GA, 5Mayo Clinic, Eyota, MN

    Background/Purpose: Cutaneous lupus erythematosus (CLE) patients report impaired quality of life due to cutaneous and psychological morbidity. Previous literature on the prevalence of comorbidities in…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology